Overview

Unlock new possibilities in mRNA research with GenScript's patented GenCap™ technologies. Our innovations are designed to elevate your mRNA research capabilities with enhanced stability, efficiency, and targeting. Additionally, we continue to introduce cutting-edge technologies, including Cap2, circular RNA, and self-amplifying RNA platforms. Partner with GenScript to drive your RNA projects forward.

  • Co-transcriptional Capping Method

    GenScript patented Capping Technology has a new co-transcriptional capping method to make mRNA, yielding high capping efficiency and mRNA with more homogenous 5’end .

    The final cap1 structure after GenScript’s co-transcriptional capping technology

    GenCap™ Technology Benefit

    • Higher capping efficiency
    • High mRNA integrity by optimized IVT conditions
    • More homogenous 5’end
  • Co-transcriptional Capping Method- Performance

    The GenCap™ optimized IVT method ensures the production of high-integrity mRNA, resulting in enhanced mRNA expression.

    Fluc mRNA Purity mRNA integrity by Bioanalyzer

    Fluc mRNA Expression in A549 Cells

  • Selection of UTRs for tissue specific targeting

    Optimizing UTR Selection for Tissue-Specific Enhanced mRNA Expression

  • Co-transcriptional Capping Method- Immunogenicity Performance

    The GenCap™ optimized IVT method ensures the production of high-integrity mRNA, significantly reducing its immunogenicity.

  • Optimized PolyA Vector

    The Optimized PolyA vector technology facilitates the stable incorporation of polyA sequences into plasmids. The uniformity of the polyA tail is crucial, as it significantly influences mRNA expression efficiency.

    Poly(A) Tail integrity Compared with other vendors

    The length of the polyA tail significantly impacts mRNA expression efficiency in cells, with tails longer than 80 adenines (80As) typically being preferred.

    Poly(A) Length Impacts Expression

More Cutting Edge Proprietary IVT Technologies Include

Cap 2 Technology

  • Novel method for in vitro cap2-mRNA synthesis
  • Improved expression compared to Cap1 RNA under stressed conditions

CircRNA Platform

  • Proprietary circular RNA design for enhanced circularization efficiency.
  • Optimized purification method for circRNA
  • IRES options for increased expression in specific cell types
Learn More

saRNA Platform

  • Proprietary saRNA design to enhance saRNA expression
  • Optimized saRNA design for reduced immunogenicity
Learn More

REQUEST A QUOTE